Please refer to Investorenkonferenzen page 1

Planegg/Martinsried (IRW-Press/28.08.2024) – Die Medigene AG (Medigene oder das “Unternehmen”, FWB: MDG1, Prime Standard) une onkological plattformunternehmen, ie de Erforschung und Entwicklung von T-Zell-Rezeptor (TCR)-gesteuerten Immuntherapies voor de behandeling Krebs spezialisiert, would op de jährlichen Herbstkonferenz of September 2 to 3, 2024 in Frankfurt at the 26th Annual Global Investment Conference of HC Wainwright from September 9 to 11, 2024 in New York and at the Baader Investment Conference from September 23 to 26, 2024 in Munich das Unternehmen in Rahmen einer Präsentation voorellen.

Unternehmenspräsentatie – Herbstkonferenz 2024

https://equityforum.de/events/herbstkonferenz-2024

Ort: Le Meridien Hotel Frankfurt, Frankfurt

Tag and Time: Monday, September 2, 2024, 10:00 AM – 10:40 AM Ortszeit

Reference: Dr. Selwyn Ho, CEO

Corporate Presentation – HC Wainwright 26th Annual Global Investment Conference 2024

https://hcwevents.com/annualconference/

Location: Lotte New York Palace, New York, USA

Tag and duration: wird noch veröffentlicht

Reference: James Cornicelli, Senior Vice President, Head of Corporate Development & Strategy

Unternehmenspräsentation – Baader Investment Conference 2024

https://www.baaderinvestmentconference.com/

Location: Hotel Sofitel Munich Bayerpost, Munich

Tag and Time: Mittwoch, September 25, 2024, 12:30 PM – 1:10 PM Ortszeit, Forum 3

Reference: Dr. Selwyn Ho, CEO

Medigene management teams are approached by registered investors for their business activities through the representation of personal relationships.

— End of the press conference —

About Medigene AG

Medigene AG (FWB: MDG1) is an immunology platform focused on the treatment of T-Zell Receptor (TCR) therapy with an effective treatment of Krebs. The end-to-end platform generates optimal 3S (sensitive, specific and safe) T-Zell receptors with unique and uncontrolled properties, which work in varying therapeutic regimens with T-Zell Receptor-modified T-Zell therapies (TCR-T), TCR-managed T-Zell engager therapies and TCR therapies with natural killer cells, so that the own product pipeline is developed as one of the partnerships.